title: A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction.
authors.forename: Emanuele
authors.initials: E
authors.lastname: Cencini
authors.forename: Elisa
authors.initials: E
authors.lastname: Sozzi
authors.forename: Anna
authors.initials: A
authors.lastname: Sicuranza
authors.forename: Alberto
authors.initials: A
authors.lastname: Fabbri
authors.forename: Donatella
authors.initials: D
authors.lastname: Raspadori
authors.forename: Francesco
authors.initials: F
authors.lastname: Lauria
authors.forename: Francesco
authors.initials: F
authors.lastname: Forconi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000502:physiology; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D000074323:Alemtuzumab; D014740:Vidarabine; C024352:fludarabine